← Back to patent-cliff list
CAS 60456-26-0
(R)-oxiran-2-ylmethyl butyrate
Codes：RIVA-024、TEDI-003
Application context (from source-drug indications)
肺栓塞利伐沙班中风利伐沙班先天性心脏缺损利伐沙班血栓形成利伐沙班静脉血栓栓塞利伐沙班冠状动脉疾病利伐沙班皮肤和皮肤结构感染泰地唑利磷酸盐葡萄球菌感染泰地唑利磷酸盐细菌性皮肤疾病泰地唑利磷酸盐
Source drugs (routes using this intermediate)
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-chloroacetyl chloride→4-(4-nitrophenyl)morpholin-3-one→4-(4-aminophenyl)morpholin-3-one→5-chlorothiophene-2-carbonyl chloride→2-(phenylamino)ethan-1-ol→4-phenylmorpholin-3-one→benzyl carbonochloridate→benzyl (4-(3-oxomorpholino)phenyl)carbamate→(R)-oxiran-2-ylmethyl butyrate→(R)-4-(4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(R)-(2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl methanesulfonate→2-methylpropan-2-amine→(S)-4-(4-(5-((tert-butylamino)methyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(S)-N-(tert-butyl)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide
3-fluoroaniline→benzyl (3-fluorophenyl)carbamate→(R)-oxiran-2-ylmethyl butyrate→(R)-3-(3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one→(R)-3-(3-fluoro-4-iodophenyl)-5-(hydroxymethyl)oxazolidin-2-one→(R)-3-(3-fluoro-4-(tributylstannyl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one→5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine→(R)-3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one→2,5-dibromopyridine→(5-(methylsulfonyl)pyridin-2-yl)methanamine hydrochloride→5-bromo-2-(2H-tetrazol-5-yl)pyridine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(4-Aminophenyl)morpholin -3-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | (S)-(+)-N-(2,3-Epoxypropyl)phthalimide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 5-Chlorothiophene-2-carboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | 5-Chlorothiophene-2-carbonyl chloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Taizhou GMP-like Site | 4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Qualified Partner — East China API Works | 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.